-+ 0.00%
-+ 0.00%
-+ 0.00%

Insights into Supernus Pharmaceuticals's Upcoming Earnings

Benzinga·02/23/2026 18:01:12
Listen to the news

Supernus Pharmaceuticals (NASDAQ:SUPN) will release its quarterly earnings report on Tuesday, 2026-02-24. Here's a brief overview for investors ahead of the announcement.

Analysts anticipate Supernus Pharmaceuticals to report an earnings per share (EPS) of $0.22.

The market awaits Supernus Pharmaceuticals's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.

It's important for new investors to understand that guidance can be a significant driver of stock prices.

Earnings History Snapshot

During the last quarter, the company reported an EPS missed by $1.42, leading to a 17.35% drop in the share price on the subsequent day.

Here's a look at Supernus Pharmaceuticals's past performance and the resulting price change:

Quarter Q3 2025 Q2 2025 Q1 2025 Q4 2024
EPS Estimate 0.62 0.42 0.37 0.52
EPS Actual -0.80 0.40 -0.21 0.27
Price Change % -17.00 13.00 -5.00 -3.00

eps graph

Market Performance of Supernus Pharmaceuticals's Stock

Shares of Supernus Pharmaceuticals were trading at $50.86 as of February 20. Over the last 52-week period, shares are up 53.41%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.

Analyst Insights on Supernus Pharmaceuticals

For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Supernus Pharmaceuticals.

A total of analyst ratings have been received for Supernus Pharmaceuticals, with the consensus rating being . The average one-year price target stands at $, suggesting a potential .

To track all earnings releases for Supernus Pharmaceuticals visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.